Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. This evidence concerns the gene BCL2 and T-cell non-Hodgkin lymphoma.